Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R Jr, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, Kirkpatrick L, Powis G.

Cancer Res. 2019 Oct 15;79(20):5457. doi: 10.1158/0008-5472.CAN-19-2586. No abstract available.

PMID:
31615811
2.

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zang S, Lemos R Jr, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, Kirkpatrick L, Powis G.

Cancer Res. 2019 Jun 15;79(12):3100-3111. doi: 10.1158/0008-5472.CAN-18-2372. Epub 2019 Apr 30. Erratum in: Cancer Res. 2019 Oct 15;79(20):5457.

PMID:
31040156
3.

Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.

Somlyai G, Collins TQ, Meuillet EJ, Hitendra P, D'Agostino DP, Boros LG.

Oncotarget. 2017 Jul 25;8(30):50187-50192. doi: 10.18632/oncotarget.16238. Review.

4.

Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor.

Kobes JE, Daryaei I, Howison CM, Bontrager JG, Sirianni RW, Meuillet EJ, Pagel MD.

Pancreas. 2016 Sep;45(8):1158-66. doi: 10.1097/MPA.0000000000000607.

5.

Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle.

Boros LG, D'Agostino DP, Katz HE, Roth JP, Meuillet EJ, Somlyai G.

Med Hypotheses. 2016 Feb;87:69-74. doi: 10.1016/j.mehy.2015.11.016. Epub 2015 Nov 26.

6.

A roadmap for interpreting (13)C metabolite labeling patterns from cells.

Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, Clish CB, DeBerardinis RJ, Feron O, Frezza C, Ghesquiere B, Gottlieb E, Hiller K, Jones RG, Kamphorst JJ, Kibbey RG, Kimmelman AC, Locasale JW, Lunt SY, Maddocks OD, Malloy C, Metallo CM, Meuillet EJ, Munger J, Nöh K, Rabinowitz JD, Ralser M, Sauer U, Stephanopoulos G, St-Pierre J, Tennant DA, Wittmann C, Vander Heiden MG, Vazquez A, Vousden K, Young JD, Zamboni N, Fendt SM.

Curr Opin Biotechnol. 2015 Aug;34:189-201. doi: 10.1016/j.copbio.2015.02.003. Epub 2015 Feb 28. Review.

7.

Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.

Nakanishi M, Perret C, Meuillet EJ, Rosenberg DW.

Carcinogenesis. 2015 Apr;36(4):478-86. doi: 10.1093/carcin/bgv004. Epub 2015 Jan 29.

8.

Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells.

Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Rezaeian AH, Lin HK, Meuillet EJ, Zhang S.

PLoS Comput Biol. 2015 Jan 8;11(1):e1004021. doi: 10.1371/journal.pcbi.1004021. eCollection 2015 Jan.

9.

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.

Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ.

Int J Nanomedicine. 2014 Dec 3;9:5653-65. doi: 10.2147/IJN.S68511. eCollection 2014.

10.

Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells.

Cantoria MJ, Boros LG, Meuillet EJ.

Metabolomics. 2014;10(1):91-104. doi: 10.1007/s11306-013-0555-4. Epub 2013 Jun 26.

11.

Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Norberg JK, Sells E, Chang HH, Alla SR, Zhang S, Meuillet EJ.

Pharm Pat Anal. 2013 Mar;2(2):265-88. doi: 10.4155/ppa.12.90. Review.

12.

Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging.

Stephen RM, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ.

Exp Biol Med (Maywood). 2012 Nov;237(11):1273-80. doi: 10.1258/ebm.2012.011326.

13.

Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells.

Medda F, Sells E, Chang HH, Dietrich J, Chappeta S, Smith B, Gokhale V, Meuillet EJ, Hulme C.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):528-31. doi: 10.1016/j.bmcl.2012.11.030. Epub 2012 Nov 21.

14.

The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.

Jandova J, Beyer TE, Meuillet EJ, Watts GS.

Cell Biochem Funct. 2012 Dec;30(8):687-95. doi: 10.1002/cbf.2853. Epub 2012 Jun 13.

15.

Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.

Smith B, Chang HH, Medda F, Gokhale V, Dietrich J, Davis A, Meuillet EJ, Hulme C.

Bioorg Med Chem Lett. 2012 May 15;22(10):3567-70. doi: 10.1016/j.bmcl.2012.03.013. Epub 2012 Mar 28.

16.

Identification and development of mPGES-1 inhibitors: where we are at?

Chang HH, Meuillet EJ.

Future Med Chem. 2011 Nov;3(15):1909-34. doi: 10.4155/fmc.11.136. Review.

17.

Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.

Chang HH, Song Z, Wisner L, Tripp T, Gokhale V, Meuillet EJ.

Invest New Drugs. 2012 Oct;30(5):1865-77. doi: 10.1007/s10637-011-9748-8. Epub 2011 Sep 20.

18.
19.

Development of sulfonamide AKT PH domain inhibitors.

Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA.

Bioorg Med Chem. 2011 Mar 15;19(6):2046-54. doi: 10.1016/j.bmc.2011.01.049. Epub 2011 Feb 1.

20.

Recent development of anticancer therapeutics targeting Akt.

Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S.

Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):146-59. Review.

21.

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2010 Mar;9(3):706-17. doi: 10.1158/1535-7163.MCT-09-0985. Epub 2010 Mar 2.

22.

mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators".

Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW.

Biochimie. 2010 Jun;92(6):660-4. doi: 10.1016/j.biochi.2010.02.006. Epub 2010 Feb 13. Review.

23.

Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.

Block KM, Wang H, Szabó LZ, Polaske NW, Henchey LK, Dubey R, Kushal S, László CF, Makhoul J, Song Z, Meuillet EJ, Olenyuk BZ.

J Am Chem Soc. 2009 Dec 23;131(50):18078-88. doi: 10.1021/ja807601b.

24.

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.

Bioorg Med Chem. 2009 Oct 1;17(19):6983-92. doi: 10.1016/j.bmc.2009.08.022. Epub 2009 Aug 19.

25.

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ.

Cancer Res. 2009 Jun 15;69(12):5073-81. doi: 10.1158/0008-5472.CAN-08-3839. Epub 2009 Jun 2.

26.

NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1).

Dexheimer TS, Carey SS, Zuohe S, Gokhale VM, Hu X, Murata LB, Maes EM, Weichsel A, Sun D, Meuillet EJ, Montfort WR, Hurley LH.

Mol Cancer Ther. 2009 May;8(5):1363-77. doi: 10.1158/1535-7163.MCT-08-1093. Epub 2009 May 12.

27.

Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells.

Berggren M, Sittadjody S, Song Z, Samira JL, Burd R, Meuillet EJ.

Nutr Cancer. 2009;61(3):322-31. doi: 10.1080/01635580802521338.

28.

Discovery of a novel class of AKT pleckstrin homology domain inhibitors.

Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ.

Mol Cancer Ther. 2008 Sep;7(9):2621-32. doi: 10.1158/1535-7163.MCT-07-2276.

29.

Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster.

Song Z, Saghafi N, Gokhale V, Brabant M, Meuillet EJ.

Exp Cell Res. 2007 Apr 1;313(6):1161-71. Epub 2007 Jan 12.

30.

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G.

Oncol Res. 2004;14(10):513-27.

PMID:
15559765
31.
32.

Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.

List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G.

Exp Hematol. 2004 Jun;32(6):526-35.

PMID:
15183893
33.

Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ, Martinez JD.

Cancer Lett. 2003 Dec 8;202(1):43-51.

PMID:
14643025
34.

Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.

Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G.

Mol Cancer Ther. 2003 Apr;2(4):389-99.

35.

Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides.

Miljan EA, Meuillet EJ, Mania-Farnell B, George D, Yamamoto H, Simon HG, Bremer EG.

J Biol Chem. 2002 Mar 22;277(12):10108-13. Epub 2002 Jan 16.

36.

Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides.

Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, Kozikowski AP.

J Med Chem. 2001 Mar 15;44(6):898-908.

PMID:
11300871
37.
38.

3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.

Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP.

J Med Chem. 2000 Aug 10;43(16):3045-51.

PMID:
10956212
39.

Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431.

Meuillet EJ, Mania-Farnell B, George D, Inokuchi JI, Bremer EG.

Exp Cell Res. 2000 Apr 10;256(1):74-82.

PMID:
10739654
40.

Metformin modulates insulin receptor signaling in normal and cholesterol-treated human hepatoma cells (HepG2).

Meuillet EJ, Wiernsperger N, Mania-Farnell B, Hubert P, Cremel G.

Eur J Pharmacol. 1999 Jul 21;377(2-3):241-52.

PMID:
10456437
41.

Incorporation of exogenous lipids modulates insulin signaling in the hepatoma cell line, HepG2.

Meuillet EJ, Leray V, Hubert P, Leray C, Cremel G.

Biochim Biophys Acta. 1999 May 31;1454(1):38-48.

42.

Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431.

Meuillet EJ, Kroes R, Yamamoto H, Warner TG, Ferrari J, Mania-Farnell B, George D, Rebbaa A, Moskal JR, Bremer EG.

Cancer Res. 1999 Jan 1;59(1):234-40.

43.

Growth factor receptors as targets for therapy in pediatric brain tumors.

Meuillet EJ, Bremer EG.

Pediatr Neurosurg. 1998 Jul;29(1):1-13. Review.

PMID:
9755305

Supplemental Content

Loading ...
Support Center